Cited 6 times in
In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa Strains at a Tertiary Hospital in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 용동은 | - |
dc.date.accessioned | 2021-09-29T00:41:02Z | - |
dc.date.available | 2021-09-29T00:41:02Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 1424-8247 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/183985 | - |
dc.description.abstract | The siderophore-antibiotic conjugate LCB10-0200 (a.k.a. GT-1) has been developed to combat multidrug-resistant Gram-negative bacteria. In this study, the in vitro activity of LCB10-0200 and LCB10-0200/avibactam (AVI) has been investigated against carbapenem-resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Minimal inhibitory concentrations (MICs) of LCB10-0200, LCB10-0200/AVI, aztreonam, aztreonam/AVI, ceftazidime, ceftazidime/AVI, and meropenem were measured using the agar dilution method. Whole genome sequencing was performed using Illumina and the resistome was analyzed. LCB10-0200 displayed stronger activity than the comparator drugs in meropenem-resistant E. coli and K. pneumoniae, and the addition of AVI enhanced the LCB10-0200 activity to MIC ≤ 0.12 mg/L for 90.5% of isolates. In contrast, whereas LCB10-0200 alone showed potent activity against meropenem-resistant A. baumannii and P. aeruginosa at MIC ≤ 4 mg/L for 84.3% of isolates, the combination with AVI did not improve its activity. LCB10-0200/AVI was active against CTX-M-, SHV-, CMY-, and KPC- producing E. coli and K. pneumoniae, while LCB10-0200 alone was active against ADC-, OXA-, and VIM- producing A. baumannii and P. aeruginosa. Both LCB10-0200 and LCB10-0200/AVI displayed low activity against IMP- and NDM- producing strains. LCB10-0200 alone exhibited strong activity against selected strains. The addition of AVI significantly increased LCB10-0200 activity against carbapenem-resistant E. coli, K. pneumoniae. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | PHARMACEUTICALS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa Strains at a Tertiary Hospital in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Laboratory Medicine (진단검사의학교실) | - |
dc.contributor.googleauthor | Le Phuong Nguyen | - |
dc.contributor.googleauthor | Chul Soon Park | - |
dc.contributor.googleauthor | Naina Adren Pinto | - |
dc.contributor.googleauthor | Hyunsook Lee | - |
dc.contributor.googleauthor | Hyun Soo Seo | - |
dc.contributor.googleauthor | Thao Nguyen Vu | - |
dc.contributor.googleauthor | Hung Mai | - |
dc.contributor.googleauthor | An H T Pham | - |
dc.contributor.googleauthor | Eris Jang | - |
dc.contributor.googleauthor | Young Lag Cho | - |
dc.contributor.googleauthor | Karrie Goglin | - |
dc.contributor.googleauthor | Kevin Nguyen | - |
dc.contributor.googleauthor | Richard White | - |
dc.contributor.googleauthor | Roshan D'Souza | - |
dc.contributor.googleauthor | Derrick E Fouts | - |
dc.contributor.googleauthor | Dongeun Yong | - |
dc.identifier.doi | 10.3390/ph14040370 | - |
dc.contributor.localId | A02423 | - |
dc.relation.journalcode | J04088 | - |
dc.identifier.pmid | 33923801 | - |
dc.subject.keyword | LCB10-0200 (GT-1) | - |
dc.subject.keyword | LCB10-0200/Avibactam | - |
dc.subject.keyword | carbapenem resistance | - |
dc.subject.keyword | siderophore-antibiotic conjugate | - |
dc.contributor.alternativeName | Yong, Dong Eun | - |
dc.contributor.affiliatedAuthor | 용동은 | - |
dc.citation.volume | 14 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 370 | - |
dc.identifier.bibliographicCitation | PHARMACEUTICALS, Vol.14(4) : 370, 2021-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.